Firebrick Pharma Limited · ASX:FRE
Firebrick Pharma — Shareholder Meeting (November 2024)
18 slides from Firebrick Pharma's shareholder meeting presentation, Nov 27, 2024
Slide 1: Chairman's Annual General Meeting Presentation
27 November 2024 ASX Announcement Chairman’s Annual General Meeting Presentation Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to provide the attached presentation and transcript to be made by the Chairman at today’s Annual General Meeting. This presentation and transcript has b
Slide 2: Presentation by Peter Molloy, Executive Chairman
For personal use only Presentation by Peter Molloy Executive Chairman Annual General Meeting 27 November 2024 Authorised for release by Peter Molloy, Executive Chairman of Firebrick Pharma Limited The World Needs
Slide 3: Notice and Disclaimer
NOTICE AND DISCLAIMER This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation
Slide 4: Our primary asset: Nasodine Nasal Spray
Our primary asset: Nasodine® Nasal Spray • Firebrick has developed the world’s first clinically-supported For personal use only povidone-iodine nasal spray, Nasodine® Nasal Spray (“Nasodine”). • In vitro, Nasodine kills all known respiratory viruses and bacteria – including pandemic strains – with n
Slide 5: One year ago…
One year ago… What Firebrick faced: What we did about it: For personal use only • Negative result in our second • We continued to believe in Phase 3 trial Nasodine and that the world • Withdrawal from AAT appeal, needed this valuable product which stopped Nasodine • We decided to make Nasodine appro
Slide 6: 1. The US launch
1. The US launch • Nasodine to be made available as ‘nasal cleanser’ For personal use only under cosmetic provisions of FD&C Act. • Created US corporation, Firebrick Pharma, Inc. with banking and credit card services. • Agreement with US manufacturer to produce Nasodine; successfully completed first
Slide 7: US sales development
US sales development US Nasodine Orders US Nasodine Units Sold (online only: nasodine.com) (online only: nasodine.com) For personal use only 100 180 90 160 80 140 70 Monthly Online Unit Sales Monthly Online Orders 120 60 100 50 Canada Canada USA 80 USA 40 60 30 40 20 10 20 0 0 Apr May Jun Jul Aug Se
Slide 8: 2. The Singapore launch – Phase 1 social media launch
2. The Singapore launch – Phase 1 Social media launch • Nasodine is a ‘topical antiseptic’ under HSA regulations. For personal use only • Manufacturing by Probiotec of the first commercial batch of Nasodine in Australia for sale in Singapore, and successful export of finished product to Singapore fo
Slide 9: Australia/Singapore sales development
Australia/Singapore sales development Aus/Sing Nasodine Orders Aus/Sing Nasodine Units Sold (online only: nasodine-sg.com) (online only: nasodine-sg.com) For personal use only 50 160 45 140 40 120 35 Monthly Online Unit Sales Monthly Online Orders 100 30 25 Singapore 80 Singapore Australia Australia
Slide 10: 2. Singapore launch – Doctor and retail pharmacy launch
2. Singapore launch – Phase 2 Doctor and retail pharmacy launch • Successfully exhibited at two key Singapore For personal use only HCP brochure used HCP conferences: WONCA (World Congress of at WONCA, SPC Family Doctors) and the Singapore Pharmacy and by Innorini Congress, introducing Nasodine to H
Slide 11: 3. The Philippines – the next launch
3. The Philippines – the next launch • Philippines FDA (PFDA) confirmed that subject to local manufacturing, Nasodine For personal use only could be launched in the Philippines as a nasal disinfectant and without further clinical studies • Existing partnership with SV More amended to include right t
Slide 12: 4. Beyond existing markets
4. Beyond existing markets • Europe For personal use only • Firebrick filed an application for approval of Nasodine in Europe as a nasal antiseptic (ASX ann. 9 Sept 2024). • Sweden’s Medical Products Agency (MPA) is leading the review, with the Icelandic Medicines Agency conducting a parallel assess
Slide 13: 5. Resourcing and funding
5. Resourcing and funding • Operating cost base greatly reduced in calendar 2024 For personal use only • Overall operating costs expected to be down by more than 50% • Reflects focus transition from R&D to commercialization, but also significant infrastructure cost reductions • Funding • In CY2024,
Slide 14: Firebrick's future is bright
Firebrick’s future is bright • Nasodine is on the market in two countries, with a third soon to be added; the For personal use only market response has been positive, endorsing the breakthrough potential of Nasodine and our new commercialisation strategy. • In Singapore, the exclusive distribution t
Slide 15: Transcript of presentation by Executive Chairman
Transcript of AGM presentation by Executive Chairman, 27 November 2024 The following are verbal comments to be made by the Executive Chairman, Dr Peter Molloy, in relation to each slide: Slides 1-3: No comments. Slide 4: One year ago, we were all reeling from the negative results of our second commo
Slide 16: For personal use only
Considering all the potential pitfalls and challenges of US commercialisation, our launch in April went smoothly, and since then, US sales have developed in a positive pattern and we have received 40 5-star reviews. We are now starting an influencer social media campaign to boost sales and accordingl
Slide 17: For personal use only
genuinely excited about the prospects for Nasodine in retail pharmacy, as are we. The launch is scheduled for January, and we are looking forward to seeing the sales offtake in calendar 2025. To support the Guardian sales, we also executed an agreement with a local logistics partner, DKSH, which wor
Slide 18: For personal use only
to commercialisation. However, it also involved significant cost-cutting that included reducing staff and consulting roles, while freezing executive salaries. This happened in a period where management bandwidth was severely stretched with everything that needed to occur around the launches in the US
Firebrick Pharma — Shareholder Meeting (November 2024) on 6ix